FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

堆栈库

Neuro Performance Stack

Cognitive Enhancementintermediate

81

协同作用

81
Share
肽类

3

平均每日mcg

1,150

级别

intermediate

添加时间

May 17, 2026

概述

The Neuro Performance Stack extends the classic Russian Brain Stack (Semax + Selank) with BPC-157, adding a gut-brain axis component and systemic healing support to the core cognitive and anxiolytic effects. This combination is particularly popular with high-performers dealing with both cognitive demands and physical stress. Semax and Selank provide the core cognitive effects: BDNF upregulation, focus, memory, and anxiolytic stability (see Russian Brain Stack for detailed mechanisms). BPC-157 adds a dimension that neither cognitive peptide addresses — the gut-brain connection. The gut-brain axis is increasingly recognized as a bidirectional communication system where GI health directly impacts cognitive function, mood, and stress resilience. BPC-157 heals the gut mucosal lining, reduces intestinal inflammation, and supports neurotransmitter production in the enteric nervous system. Users with gut dysfunction often find that cognitive peptides underperform until the gut component is addressed. Beyond gut-brain axis effects, BPC-157 has direct central nervous system activity. It modulates dopaminergic signaling, has demonstrated neuroprotective effects in animal models of brain injury, and supports peripheral nerve regeneration. In the context of this stack, BPC-157 provides a supportive background of neural tissue health that complements Semax''s acute BDNF upregulation. This stack is particularly well-suited for practitioners, executives, athletes, and high-performers who face both cognitive demands and physical stress — situations where the body''s healing capacity and cognitive performance are both taxed simultaneously.

给药方案

Semax

Every day· intranasal

了解更多关于Semax →

600 mcg

每剂

Selank

Every day· intranasal

了解更多关于Selank →

300 mcg

每剂

BPC-157

Every day· subcutaneous

了解更多关于BPC-157 →

250 mcg

每剂

目标与证据

Cognitive performanceAnxiety reductionGut-brain healthNeural protectionStress resilience
证据等级:动物研究

警告

  • BPC-157 was removed from the FDA Category 2 list (April 2026) but remains under PCAC review (July 23, 2026) — not legal to compound yet.

Comments

Sign in to join the discussion

免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。